NYSE:XON - Intrexon Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.39 +0.07 (+1.62 %) (As of 04/26/2019 03:37 AM ET)Previous Close$4.32Today's Range$4.20 - $4.505052-Week Range$3.95 - $19.94Volume1.69 million shsAverage Volume2.47 million shsMarket Capitalization$705.56 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland. Receive XON News and Ratings via Email Sign-up to receive the latest news and ratings for XON and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNYSE:XON Previous Symbol CUSIPN/A CIK1356090 Webwww.dna.com Phone301-556-9900Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares160,720,000Market Cap$705.56 million Next Earnings Date5/9/2019 (Estimated) OptionableOptionable Intrexon (NYSE:XON) Frequently Asked Questions What is Intrexon's stock symbol? Intrexon trades on the New York Stock Exchange (NYSE) under the ticker symbol "XON." How were Intrexon's earnings last quarter? Intrexon Corp (NYSE:XON) issued its quarterly earnings data on Thursday, February, 28th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.14. The biotechnology company had revenue of $43.19 million for the quarter, compared to the consensus estimate of $61.81 million. View Intrexon's Earnings History. When is Intrexon's next earnings date? Intrexon is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Intrexon. What price target have analysts set for XON? 4 equities research analysts have issued 12 month price objectives for Intrexon's shares. Their forecasts range from $12.00 to $72.00. On average, they expect Intrexon's stock price to reach $42.3333 in the next twelve months. This suggests a possible upside of 864.3% from the stock's current price. View Analyst Price Targets for Intrexon. What is the consensus analysts' recommendation for Intrexon? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intrexon in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intrexon. Has Intrexon been receiving favorable news coverage? News headlines about XON stock have been trending somewhat negative on Friday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Intrexon earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. Are investors shorting Intrexon? Intrexon saw a increase in short interest during the month of April. As of April 15th, there was short interest totalling 35,827,689 shares, an increase of 0.4% from the March 29th total of 35,701,199 shares. Based on an average trading volume of 1,836,570 shares, the days-to-cover ratio is currently 19.5 days. Approximately 50.7% of the shares of the stock are sold short. View Intrexon's Current Options Chain. Who are some of Intrexon's key competitors? Some companies that are related to Intrexon include Medpace (MEDP), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX), BIOQUAL (BIOQ), Vitality Biopharma (VBIO), HedgePath Pharmaceuticals (HPPI), Bioanalytical Systems (BASI), Cleveland BioLabs (CBLI), Tenax Therapeutics (TENX) and US Stem Cell (USRM). What other stocks do shareholders of Intrexon own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intrexon investors own include Nordic American Tanker (NAT), ZIOPHARM Oncology (ZIOP), Hess (HES), Boeing (BA), Opko Health (OPK), Celldex Therapeutics (CLDX), Gilead Sciences (GILD), Alibaba Group (BABA), General Electric (GE) and Micron Technology (MU). Who are Intrexon's key executives? Intrexon's management team includes the folowing people: Mr. Randal J. Kirk, Chairman & CEO (Age 65)Mr. Rick L. Sterling, Chief Financial Officer (Age 54)Mr. Donald P. Lehr, Chief Legal Officer & Corp. Sec. (Age 43)Mr. Robert F. Walsh III, Sr. VP of Energy & Fine Chemicals Platforms (Age 60)Mr. Jeffrey Thomas Perez, Sr. VP of Intellectual Property Affairs (Age 46) Who are Intrexon's major shareholders? Intrexon's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sanders Morris Harris LLC (0.14%), BNP Paribas Arbitrage SA (0.06%), Virtu Financial LLC (0.02%), Jupiter Wealth Management LLC (0.01%), Addison Capital Co (0.01%) and Valeo Financial Advisors LLC (0.01%). Company insiders that own Intrexon stock include Andrew J Last, Dean J Mitchell, Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk, Rick L Sterling, Robert B Shapiro and Thomas D Reed. View Institutional Ownership Trends for Intrexon. Which major investors are buying Intrexon stock? XON stock was bought by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Sanders Morris Harris LLC, Virtu Financial LLC, Jupiter Wealth Management LLC, Addison Capital Co, Truvestments Capital LLC and Valeo Financial Advisors LLC. Company insiders that have bought Intrexon stock in the last two years include Andrew J Last, Dean J Mitchell, Donald P Lehr, Jeffrey Thomas Perez, Randal J Kirk and Robert B Shapiro. View Insider Buying and Selling for Intrexon. How do I buy shares of Intrexon? Shares of XON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Intrexon's stock price today? One share of XON stock can currently be purchased for approximately $4.39. How big of a company is Intrexon? Intrexon has a market capitalization of $705.56 million. What is Intrexon's official website? The official website for Intrexon is http://www.dna.com. How can I contact Intrexon? Intrexon's mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company can be reached via phone at 301-556-9900 or via email at [email protected] MarketBeat Community Rating for Intrexon (NYSE XON)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 331 (Vote Outperform)Underperform Votes: 308 (Vote Underperform)Total Votes: 639MarketBeat's community ratings are surveys of what our community members think about Intrexon and other stocks. Vote "Outperform" if you believe XON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XON will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/26/2019 by MarketBeat.com StaffFeatured Article: Day Trading - Risk Worth the Reward?